MedTrace Logo

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-07-29

No results posted yet for this study

Summary

Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.

Conditions

Interventions

DRUG

Regular Human Insulin

Individual dose of RHI administered subcutaneously

DRUG

Lispro

Individual dose of lispro administered subcutaneously

DRUG

VIAject

Individual dose of VIAject administered subcutaneously

DRUG

VIAject 50%

Individual dose of VIAject 50% administered subcutaneously

DRUG

VIAject/Insulin Glargine

VIAject mixed wiht insulin glargine and administered subcutaneously

DRUG

Insulin Glargine/VIAject

Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously

Sponsors & Collaborators

  • Biodel

    lead INDUSTRY

Principal Investigators

  • Marcus Hompesch, MD · Profil Institute for Clinical Research, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01000922 on ClinicalTrials.gov